Bioventus EV/EBIT BVS

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2022.

Today, Oct 23, 2026: 26.2×
5-year median: 24.5×
Against its 5-year history: 55th; percentile: 0 is its lowest day, 100 its highest
5-year range: 3.1× to 211×
Peer median: 24.1×

Bioventus' EV/EBIT is 26.2× as of Oct 23, 2026.

That is above its 5-year median of 24.5×, close to the middle of its last 5 years.

Over that time it ranged from 3.1× in Mar 2023 to 211× in Nov 2024.

The median for 10 medical instruments and supplies stocks of a similar size is 24.1×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	26.2×	17.1×	26.2×
2025	22.3×	21.6×	150×
2024	149×	53.4×	211×
2023	3.9×	3.1×	4.3×
2022	3.8×	3.6×	61.7×

Against its peers

Companies in Medical - Instruments & Supplies nearest Bioventus' size, closest first, today.

Company	EV/EBIT
BVSBioventus	26.2×
CDRECadre	23.2×
STAAStaar Surgical	57.7×
IRMDIradimed	37.7×
EYENational Vision	19.2×
LMATLemaitre Vascular	22.6×
INSPInspire Medical Systems	32.6×
MOVMovado	11.8×
UFPTUFP Technologies	24.9×
MDXGMimedx	51.6×
TCMDTactile Systems Technology	13.3×
Peer median	24.1×

Where Bioventus ranks

#29of 46Medical instruments and supplies stocks with the lowest EV/EBIT

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Bioventus

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.